biostudies-literatureWong Chong EThis project was funded with an establishment grant for new investigators of the Oncology research axis from the CHU de Québec.1049https://www.ebi.ac.uk/biostudies/studies/S-EPMC9535963biostudies-literatureUnknown22(1)<h4>Background / synopsis</h4>Cholesterol and lipids play an important role in sustaining tumor growth and metastasis in a large variety of cancers. ANGPTL3 and PCSK9 modify circulating cholesterol levels, thus availability of lipids to peripheral cells. Little is known on the role, if any, of circulating lipid-related factors such as PCSK9, ANGPTL3 and lipoprotein (a) in cancers.<h4>Objective/purpose</h4>To compare circulating levels of PCSK9, ANGPTL3, and Lp(a) in women with stage III breast cancer versus women with premalignant or benign breast lesions.<h4>Methods</h4>Twenty-three plasma samples from women diagnosed with a stage III breast cancer (ductal, lobular or mixed) were matched for age with twenty-three plasma samples from women bearing premalignant (stage 0, n = 9) or benign (nBMC cancerCirculating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.PMC9535963NAGangloff AJoncas FHSeidah NGWong Chong ECalon FDiorio CfalseCirculating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.<h4>Background / synopsis</h4>Cholesterol and lipids play an important role in sustaining tumor growth and metastasis in a large variety of cancers. ANGPTL3 and PCSK9 modify circulating cholesterol levels, thus availability of lipids to peripheral cells. Little is known on the role, if any, of circulating lipid-related factors such as PCSK9, ANGPTL3 and lipoprotein (a) in cancers.<h4>Objective/purpose</h4>To compare circulating levels of PCSK9, ANGPTL3, and Lp(a) in women with stage III breast cancer versus women with premalignant or benign breast lesions.<h4>Methods</h4>Twenty-three plasma samples from women diagnosed with a stage III breast cancer (ductal, lobular or mixed) were matched for age with twenty-three plasma samples from women bearing premalignant (stage 0, n = 9) or benign (n2022-01-01T00:00:00Z2022 Oct2025-04-22T21:52:41.372Z2025-02-19T01:27:52.25ZS-EPMC95359633620312210.1186/s12885-022-10120-6